MX2023012852A - Quimeras que tienen como diana la desubiquitinasa y metodos relacionados. - Google Patents

Quimeras que tienen como diana la desubiquitinasa y metodos relacionados.

Info

Publication number
MX2023012852A
MX2023012852A MX2023012852A MX2023012852A MX2023012852A MX 2023012852 A MX2023012852 A MX 2023012852A MX 2023012852 A MX2023012852 A MX 2023012852A MX 2023012852 A MX2023012852 A MX 2023012852A MX 2023012852 A MX2023012852 A MX 2023012852A
Authority
MX
Mexico
Prior art keywords
deubiquitinase
related methods
targeting chimeras
well
target protein
Prior art date
Application number
MX2023012852A
Other languages
English (en)
Inventor
Daniel K Nomura
Lydia Boike
Dustin Leard Dovala
Nathaniel James Henning
Matthew James Hesse
Gang Liu
Jeffrey M Mckenna
Markus Eberhard Schirle
Jessica Nichole Spradlin
John A Tallarico
Carl C Ward
Melissa Pighetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023012852A publication Critical patent/MX2023012852A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen compuestos bifuncionales, así como sales, hidratos, solvatos, profármacos, estereoisómeros o tautómeros farmacéuticamente aceptables de estos, que actúan reclutando ciertas desubiquitinasas a una proteína diana para la modulación (p. ej., estabilización) de la proteína diana, así como métodos de uso de estos.
MX2023012852A 2021-04-29 2022-04-29 Quimeras que tienen como diana la desubiquitinasa y metodos relacionados. MX2023012852A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163181796P 2021-04-29 2021-04-29
US202163186739P 2021-05-10 2021-05-10
US202163273118P 2021-10-28 2021-10-28
US202263311781P 2022-02-18 2022-02-18
PCT/US2022/027120 WO2022232634A1 (en) 2021-04-29 2022-04-29 Deubiquitinase-targeting chimeras and related methods

Publications (1)

Publication Number Publication Date
MX2023012852A true MX2023012852A (es) 2024-01-15

Family

ID=81748638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012852A MX2023012852A (es) 2021-04-29 2022-04-29 Quimeras que tienen como diana la desubiquitinasa y metodos relacionados.

Country Status (9)

Country Link
EP (1) EP4329815A1 (es)
JP (1) JP2024515828A (es)
KR (1) KR20240004584A (es)
AU (1) AU2022265718A1 (es)
BR (1) BR112023022315A2 (es)
CA (1) CA3216614A1 (es)
IL (1) IL307863A (es)
MX (1) MX2023012852A (es)
WO (1) WO2022232634A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021982A2 (en) 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CA2689429C (en) 2007-06-15 2012-08-21 Banyu Pharmaceutical Co., Ltd. Bicycloaniline derivatives
WO2009108245A2 (en) 2007-12-21 2009-09-03 University Of Virginia Patent Foundation System, method and computer program product for protecting software via continuous anti-t ampering and obfuscation transforms
ES2430053T3 (es) 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
CZ2009620A3 (cs) 2009-09-22 2011-04-06 Ústav makromolekulární chemie AV CR, v.v.i. Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AU2011242454A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EA201591177A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения для ингибирования канала cftr
WO2014097147A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
WO2018037350A1 (en) 2016-08-23 2018-03-01 Laurus Labs Limited Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof
KR20210020107A (ko) * 2018-06-13 2021-02-23 암피스타 테라퓨틱스 엘티디 UchL5 표적화를 위한 이중작용성 분자
KR20210130195A (ko) * 2019-02-21 2021-10-29 로키 테라퓨틱스 리미티드 생존-표적화 키메라 (surtac) 분자
WO2021146390A1 (en) * 2020-01-14 2021-07-22 The Trustees Of Columbia University In The City Of New York Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases

Also Published As

Publication number Publication date
KR20240004584A (ko) 2024-01-11
CA3216614A1 (en) 2022-11-03
BR112023022315A2 (pt) 2024-02-20
EP4329815A1 (en) 2024-03-06
IL307863A (en) 2023-12-01
WO2022232634A1 (en) 2022-11-03
AU2022265718A1 (en) 2023-11-02
JP2024515828A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
CR20220351A (es) Inhibidores de proteínas kras mutantes
CR20220258A (es) Inhibidores de kras g12c
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
CR20220354A (es) Inhibidores de egfr
MX2023010043A (es) Moduladores del receptor de androgenos y metodos para su uso.
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
EA202193015A1 (ru) Ингибиторы cdk
MX2007012703A (es) Compuestos de piperazina o diaza-ciclicos sustituidos por 2-amino-carbonilo como moduladores del inhibidor de la proteina de apoptosis (iap).
MX2020006071A (es) Nuevas formas solidas de cannabidiol y sus usos.
MX2021011606A (es) Compuestos dirigidos a prmt5.
CR20200652A (es) Compuestos que aumentan la actividad del proteosoma
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX2022006653A (es) Compuestos para modular la actividad de fxr y usos de los mismos.
WO2021079196A3 (en) Mettl3 modulators
NZ778087A (en) Pyrrolopyrimidine derivative and use thereof
MX2020011089A (es) Compuestos antiproliferacion y usos de los mismos.
CR20220029A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
MX2021012278A (es) Azinas condensadas para la modulacion de ep300 o cbp e indicaciones de estos.
MX2021012105A (es) Compuestos de pirrol.
MX2020008076A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor